drugset
drugset / Trial / NCT03245853

Epi-On Corneal Crosslinking for Keratoconus

NCT03245853 ↗

Phase 4 Completed 20 enrolled Comprehensive EyeCare of Central Ohio Glaukos Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

Epithelium-On Corneal Crosslinking for Keratoconus.

Timeline

Start
2017-07-18
Primary completion
2019-09-01
Completion
2019-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Riboflavin-5-phosphate Other / unclassified 1.46 mg/ml —

Indications

keratoconus